Zoryl M 1 Forte Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The extended-release formulation of Zoryl M 1 Forte Tablet PR allows for sustained drug release, promoting better adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target glycemic levels. It is essential to monitor blood glucose regularly and adjust dosage based on therapeutic response and tolerance. Contraindications include patients with renal impairment, metabolic acidosis, or hypersensitivity to either component. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Zoryl M 1 Forte Tablet PR should be used under medical supervision with appropriate lifestyle modifications to optimize diabetes management and reduce the risk of complications.